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Introduction {#jcmm13093-sec-0001}
============

Systemic lupus erythematosus (SLE) is a systemic autoimmune disorder involving multiple organs and tissues such as skin, kidneys, joints, lung and central nervous system. The aetiology and pathogenesis of SLE generally considers an involvement of environmental factors, which could trigger abnormal autoimmune responses in individuals who carry a predisposing genetic background [1](#jcmm13093-bib-0001){ref-type="ref"}. Therefore, genetic variants within immune‐modulating genes may confer the risk of SLE.

Leptin is an adipokine that plays a key role in the modulation of immune responses and the development and maintenance of inflammation [2](#jcmm13093-bib-0002){ref-type="ref"}. It is a 16‐kD non‐glycosylated polypeptide hormone mainly produced by white adipose tissue (WAT), encoding by the *obese (ob)* gene of murine homolog of human *LEP* gene [3](#jcmm13093-bib-0003){ref-type="ref"}. Investigations have shown that leptin is increased during acute infection and inflammation, indicating that leptin acts as a pro‐inflammatory cytokine. It enhances macrophage phagocytosis activity and stimulates them to produce several pro‐inflammatory cytokines, such as IL‐1, IL‐6 and TNF‐α [4](#jcmm13093-bib-0004){ref-type="ref"}. Leptin exerts its biological actions through the activation of leptin receptor, which belongs to the class 1 cytokine receptor superfamily and are encoded by the *diabetes (db)* gene [5](#jcmm13093-bib-0005){ref-type="ref"}. Numerous studies have shown abnormal increase in serum/plasma leptin levels in patients with SLE [6](#jcmm13093-bib-0006){ref-type="ref"}, [7](#jcmm13093-bib-0007){ref-type="ref"}, [8](#jcmm13093-bib-0008){ref-type="ref"}, [9](#jcmm13093-bib-0009){ref-type="ref"}, but the data regarding association between leptin‐related gene polymorphisms and SLE is still very limited. Afroze *et al*. [10](#jcmm13093-bib-0010){ref-type="ref"} showed that a *LEPR* gene polymorphism (*LEPR Q223R*) was associated with SLE susceptibility in a Kashmiri population. A recent study assessed *LEP* and *LEPR* gene polymorphisms in four different ancestral groups with SLE, but the results did not support associations between leptin‐related polymorphisms and increased SLE susceptibility [11](#jcmm13093-bib-0011){ref-type="ref"}. In this study, we carried out a case--control study to explore whether *LEP* and *LEPR* gene polymorphisms are associated with SLE susceptibility in a Chinese population.

Materials and methods {#jcmm13093-sec-0002}
=====================

Study participants {#jcmm13093-sec-0003}
------------------

A total of 633 patients with SLE were recruited from the Department of Rheumatology and Immunology at the First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital and Anqing Hospital Affiliated to Anhui Medical University. All patients met the 1997 American College of Rheumatology (ACR) revised criteria for the classification of SLE [12](#jcmm13093-bib-0012){ref-type="ref"}. The disease severity was quantified according to the SLE disease activity index 2000 (SLEDAI‐2K) [13](#jcmm13093-bib-0013){ref-type="ref"}. More active SLE was defined as a SLEDAI‐2K score \>10, and those patients with SLEDAI‐2K ≤10 were classed as relatively inactive [14](#jcmm13093-bib-0014){ref-type="ref"}, [15](#jcmm13093-bib-0015){ref-type="ref"}. Normal controls were recruited from the general population and healthy blood donors and were geographically and ethnically matched with patients with SLE. All the normal controls did not have a history of SLE, other inflammatory/autoimmune diseases or cancer. The demographic and clinical features were collected from the medical records or by questionnaire and reviewed by experienced physicians. The study was approved by the Medical Ethics Committee of Anhui Medical University. All participants were enrolled after informed consent had been obtained.

SNP selection, genotyping and enzyme‐linked immunosorbent assay (ELISA) {#jcmm13093-sec-0004}
-----------------------------------------------------------------------

We conducted a search for the *LEP* and *LEPR* gene single‐nucleotide polymorphisms (SNPs) with a minor allele frequency (MAF) ≥0.05 within the Han Chinese population (CHB) of Beijing, China, as listed in the international HapMap Project databank (<http://hapmap.ncbi.nlm.nih.gov/cgi-perl/gbrowse/hapmap24_B36/>; HapMap Data Rel 24/phasell Nov08, on NCBI B36 assembly, dbSNP b126). Then, linkage disequilibrium (LD) analysis with an *r* ^2^ threshold of 0.8 was performed with Haploview 4.2 software (Broad Institute, Cambridge, MA, USA) for tagging SNP selection. Under these criteria, six tag SNPs in *LEP* and 26 tag SNPs in *LEPR* were selected for further evaluation. We used the bioinformatics tools F‐SNP (<http://com> pbio.cs.queensu.ca/F‐SNP/) and SNP function prediction (<http://snpinfo.niehs.nih.gov/snpinfo/snpfunc.htm>) to assess the predicted functional effects of each tag SNP [16](#jcmm13093-bib-0016){ref-type="ref"}, [17](#jcmm13093-bib-0017){ref-type="ref"}. The test for functional SNP aimed to evaluate the potentially deleterious functional impact at the splicing, transcriptional, translational and post‐translational level. The basic information of these tag SNPs is shown in Table [S1](#jcmm13093-sup-0001){ref-type="supplementary-material"}. In addition, the existing literature studies about the *LEP* and *LEPR* gene polymorphisms were reviewed. Finally, a total of four tag SNPs (rs11761556, rs12706832, rs2071045 and rs2167270) in *LEP* and nine tag SNPs \[rs10749754, rs1137100, rs1137101, rs13306519, rs8179183 (rs1805094), rs1805096, rs3790434, rs3806318 and rs7518632\] in *LEPR* were included for genotyping in our study cohort. The selected SNPs were genotyped in both case and control groups performed with improved multiple ligase detection reaction (iMLDR) genotyping assays, with technical support from the Center for Genetic & Genomic Analysis, Genesky Biotechnologies Inc., Shanghai.

Serum leptin level was determined by ELISA kits according to the manufacturer\'s instruction (R&D Systems, Inc. Minneapolis, MN, USA), and the results were expressed as nanogram per millilitre.

Statistical analysis {#jcmm13093-sec-0005}
--------------------

Differences in genotype and allele frequencies between the two groups were analysed using chi‐square or Fisher\'s exact test. Comparisons of serum leptin level between different groups of clinical features and genotypes were conducted using nonparametric test. Odds ratios (*ORs*) and 95% confidence interval (*CIs*) were estimated by non‐conditional logistic regression analyses. All these statistical analyses were performed using SPSS 10.01 software (SPSS Inc., Chicago, IL, USA).

Hardy--Weinberg equilibrium (HWE) was evaluated in normal controls, and haplotype tests were performed by the SHEsis software (<http://analysis.bio-x.cn/myAnalysis.php>) [18](#jcmm13093-bib-0018){ref-type="ref"}. A two‐sided *P* value of \<0.05 was considered as statistically significant. The Bonferroni correction was used for multiple testing.

Results {#jcmm13093-sec-0006}
=======

In this study, we included a total of 633 SLE cases and 559 healthy controls. In patients, there were 60 males and 573 females with a mean age of 39.40 ± 12.74 years, while six males and 553 females in controls with a mean age of 42.92 ± 16.57 years. The clinical features of the patients are shown in Table [1](#jcmm13093-tbl-0001){ref-type="table-wrap"}. The main clinical manifestations were arthritis (46.52%), malar rash (36.47%), renal disorder (12.64%) and oral ulcers (11.99%) (Table [1](#jcmm13093-tbl-0001){ref-type="table-wrap"}). The observed genotype frequencies of all detected SNPs were distributed in compliance with the HWE in control groups (all *P* \> 0.05).

###### 

Demographic characteristics and clinical features of 633 patients with SLE

  Characteristics                  Patients with SLE (*n* = 633)
  -------------------------------- -------------------------------
  *Demographic characteristics*    
  Age, year                        39.4 ± 12.74
  Male, *n* (%)                    60 (9.48)
  Female, *n* (%)                  573 (90.52)
  *Clinical manifestations*        
  Malar rash, *n* (%)              225 (36.47)
  Discoid rash, *n* (%)            65 (10.53)
  Photosensitivity, *n* (%)        57 (9.24)
  Oral ulcers, *n* (%)             74 (11.99)
  Arthritis, *n* (%)               287 (46.52)
  Pleurisy, *n* (%)                22 (3.57)
  Pericarditis, *n* (%)            16 (2.59)
  Renal disorder, *n* (%)          78 (12.64)
  Neurological disorder, *n* (%)   22 (3.57)

*n*: number; SLE: systemic lupus erythematosus.
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Association of *LEP* and *LEPR* gene polymorphisms with risk of SLE {#jcmm13093-sec-0007}
-------------------------------------------------------------------

The result of allele frequency and genotype frequency of 13 SNPs in patients with SLE and controls are shown in Tables [2](#jcmm13093-tbl-0002){ref-type="table-wrap"} & [3](#jcmm13093-tbl-0003){ref-type="table-wrap"}. There were no significant differences in allele and genotype distribution between patients with SLE and controls in all of these SNPs (all *P* \> 0.05). We also evaluated the association of *LEP* and *LEPR* gene polymorphisms with SLE under dominant, recessive and additive model (Tables [2](#jcmm13093-tbl-0002){ref-type="table-wrap"} & [3](#jcmm13093-tbl-0003){ref-type="table-wrap"}). Consistently, none of these polymorphisms achieved a significant difference between cases and controls (all *P* \> 0.05).

###### 

Genotype frequencies of *LEP* SNPs in patients with SLE and healthy controls

  SNP              Analysed model         SLE (*N* = 633)   Control (*N* = 559)   *P* value[a](#jcmm13093-note-0004){ref-type="fn"}
  ---------------- ---------------- ----- ----------------- --------------------- ---------------------------------------------------
  rs11761556       Genetypes        AA    337               305                   0.962
  CA               249              211   0.740                                   
  CC               47               43                                            
  Additive model   AA               337   305               0.962                 
  CC               47               43                                            
  rs12706832       Genetypes        GG    347               317                   0.924
  GA               249              209   0.813                                   
  AA               37               33                                            
  Additive model   GG               347   317               0.924                 
  AA               37               33                                            
  rs2071045        Genetypes        CC    191               187                   0.774
  CT               336              263   0.087                                   
  TT               106              109                                           
  Additive model   CC               191   187               0.774                 
  TT               106              109                                           
  rs2167270        Genetypes        GG    391               369                   0.727
  GA               215              167   0.760                                   
  AA               27               23                                            
  Additive model   GG               391   369               0.726                 
                   AA               27    23                                      

*N*: number; SNP: single‐nucleotide polymorphism; OR: odds ratio; CI: confidence interval.

The *P* values are not corrected for multiple testings, Bonferroni corrected *P* = 0.0167.

John Wiley & Sons, Ltd

###### 

Genotype frequencies of *LEPR* SNPs in patients with SLE and healthy control

  SNP              Analysed model         SLE (*N* = 633)   Control (*N* = 559)                             *P* value[a](#jcmm13093-note-0006){ref-type="fn"}
  ---------------- ---------------- ----- ----------------- ----------------------------------------------- ---------------------------------------------------
  rs10749754       Genetypes        AA    468               415                                             0.801
  GA               156              135   0.766                                                             
  GG               9                9                                                                       
  Additive model   AA               468   415               0.801                                           
  GG               9                9                                                                       
  rs1137100        Genetypes        GG    440               385                                             0.095
  GA               165              160   0.055                                                             
  AA               28               14                                                                      
  Additive model   GG               440   385               0.091                                           
  AA               28               14                                                                      
  rs1137101        Genetypes        GG    478               427                                             0.987
  GA               145              123   0.901                                                             
  AA               10               9                                                                       
  Additive model   GG               478   427               0.987                                           
  AA               10               9                                                                       
  rs13306519       Genetypes        CC    426               393                                             0.106
  CG               171              145   0.208                                                             
  GG               36               21                                                                      
  Additive model   CC               426   393               0.103                                           
  GG               36               21                                                                      
  rs8179183        Genetypes        CC    579               502                                             0.283
  GC               53               54    0.356                                                             
  GG               1                3                                                                       
  Additive model   CC               579   502               0.343[b](#jcmm13093-note-0007){ref-type="fn"}   
  GG               1                3                                                                       
  rs1805096        Genetypes        AA    480               437                                             0.508
  GA               145              112   0.327                                                             
  GG               8                10                                                                      
  Additive model   AA               480   437               0.506                                           
  GG               8                10                                                                      
  rs3790434        Genetypes        CC    446               415                                             0.235
  CT               178              130   0.088                                                             
  TT               9                14                                                                      
  Additive model   CC               446   415               0.230                                           
  TT               9                14                                                                      
  rs3806318        Genetypes        AA    512               448                                             0.262
  GA               112              107   0.214                                                             
  GG               9                4                                                                       
  Additive model   AA               512   448               0.279[b](#jcmm13093-note-0007){ref-type="fn"}   
  GG               9                4                                                                       
  rs7518632        Genetypes        AA    403               352                                             0.324
  CA               198              186   0.230                                                             
  CC               32               21                                                                      
  Additive model   AA               403   352               0.323                                           
  CC               32               21                                                                      

*N*: number; SNP: single‐nucleotide polymorphism; OR: odds ratio; CI: confidence interval.

The *P* values are not corrected for multiple testings, Bonferroni corrected *P* = 0.0167.

Calculated by Fisher\'s exact test (exact *P* value).
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Association of *LEP* and *LEPR* gene polymorphisms with clinical features in patients with SLE {#jcmm13093-sec-0008}
----------------------------------------------------------------------------------------------

To examine the potential genetic association between leptin‐related gene polymorphisms and specific clinical features in SLE, we conducted a case‐only analysis and summarized the results in Tables [4](#jcmm13093-tbl-0004){ref-type="table-wrap"} & [5](#jcmm13093-tbl-0005){ref-type="table-wrap"}. In *LEP*, the TT genotype and T allele frequencies of the rs2071045 polymorphism were significantly higher in patients with pericarditis compared with patients without this feature (*P* = 0.012, *P* = 0.011, respectively). The A allele of the rs11761556 was significantly higher in patients with malar rash (*P* = 0.044). However, no significant associations between other SNPs in *LEP* and clinical features of SLE were observed. In *LEPR*, the GA/GG genotype and G allele frequencies of the rs3806318 polymorphism achieved significant difference between patients with and without photosensitivity (*P* = 0.013, *P* = 0.008, respectively). In addition, the GA/AA genotype and A allele of rs1137100 also demonstrated an increased risk of photosensitivity (*P* = 0.043, *P* = 0.018, respectively) in patients with SLE. No significant associations of other SNPs in *LEPR* with clinical features were found. Furthermore, there was no significant difference in the genotype distribution between patients with SLEDAI \>10 and patients with SLEDAI ≤10 (Tables [4](#jcmm13093-tbl-0004){ref-type="table-wrap"} & [5](#jcmm13093-tbl-0005){ref-type="table-wrap"}).

###### 

The positive findings of association between genotype frequencies in *LEP* and clinical characteristics

  Gene (SNP)   Allele   Clinical features   Group      Genetypes *n* (%)   *P* value[a](#jcmm13093-note-0009){ref-type="fn"}       
  ------------ -------- ------------------- ---------- ------------------- --------------------------------------------------- --- -----------
  rs2071045    C/T      Pericarditis        Positive   2                   7                                                   7   **0.012**
  Negative     181      322                 98                                                                                     

*n*: number; SNP: single‐nucleotide polymorphism; M: major alleles; m: minor alleles; SLEDAI: systemic lupus erythematosus disease activity index.

The *P* values are not corrected for multiple testings, Bonferroni corrected *P* = 0.0167. Bold value means *P*\<0.05.
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###### 

The positive findings of association between genotype frequencies in *LEPR* and clinical characteristics

  Gene (SNP)                Allele                      Clinical features   Group      Genetypes *n* (%)   *P* value[a](#jcmm13093-note-0011){ref-type="fn"}        
  ------------------------- --------------------------- ------------------- ---------- ------------------- ---------------------------------------------------- --- -----------
  rs1137100                 G/A                         Photosensitivity    Positive   34                  17                                                   6   **0.043**
  Negative                  396                         142                 22                                                                                      
  rs3806318                 A/G                         Photosensitivity    Positive   40                  14                                                   3   **0.013**
  Negative                  458                         96                  6                                                                                       
  Arthritis                 Positive                    237                 43         7                   **0.045**                                                
  Negative                  261                         67                  2                                                                                       
  SLEDAI                    More active (SLEDAI \>10)   33                  3          2                   **0.020** [b](#jcmm13093-note-0012){ref-type="fn"}       
  Less active (SLEDAI≤10)   37                          16                  1                                                                                       

*n*: number; SNP: single‐nucleotide polymorphism; M: major alleles; m: minor alleles; SLEDAI: systemic lupus erythematosus disease activity index.

The *P* values are not corrected for multiple testings, Bonferroni corrected *P* = 0.0167. Bold value means *P*\<0.05.

Calculated by Fisher\'s exact test (exact *P* value).
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Association of serum leptin levels with *LEP* and *LEPR* genotypes in patients with SLE {#jcmm13093-sec-0009}
---------------------------------------------------------------------------------------

We examined the associations between serum leptin levels with different *LEP* and *LEPR* genotypes (Table [6](#jcmm13093-tbl-0006){ref-type="table-wrap"}). However, no significant differences in serum leptin levels were observed between patients with different *LEP* or *LEPR* genotypes.

###### 

Association of serum leptin levels with genotype in *LEP* and *LEPR*

  SNP          Genetypes   Number                Serum leptin level   *P* value
  ------------ ----------- --------------------- -------------------- -----------
  rs11761556   AA          46                    6.43 (3.75, 19.60)   0.838
  CA           37          6.34 (3.66, 18.54)                         
  CC           8           8.87 (3.03, 13.14)                         
  rs12706832   GG          49                    7.12 (3.94, 19.29)   0.334
  GA           36          5.75 (3.35, 16.53)                         
  AA           6           12.53 (5.60, 21.25)                        
  rs2071045    CC          30                    7.14 (3.59, 19.56)   0.928
  CT           47          5.86 (4.07, 20.36)                         
  TT           14          8.87 (3.41, 16.45)                         
  rs2167270    GG          57                    7.12 (3.73, 20.02)   0.428
  GA           31          5.85 (3.38,14.66)                          
  AA           3           13.49 (6.17,18.98)                         
  rs10749754   AA          69                    6.34 (3.57, 18.39)   0.832
  GA           18          5.53 (4.32, 19.51)                         
  GG           4           14.27 (4.20, 20.89)                        
  rs1137100    GG          67                    6.34 (3.61, 19.17)   0.454
  GA           18          11.26 (4.89, 19.51)                        
  AA           6           5.13 (2.38, 15.95)                         
  rs1137101    GG          72                    6.41 (3.63, 18.69)   0.955
  GA           16          5.47 (4.15, 20.08)                         
  AA           3           12.52 (1.43, 16.02)                        
  rs13306519   CC          63                    8.21 (4.11, 19.17)   0.186
  CG           21          5.05 (3.44, 12.46)                         
  GG           7           16.70 (5.29, 22.51)                        
  rs8179183    CC          81                    7.12 (3.70, 19.29)   0.113
  GC           10          4.40 (3.85, 7.29)                          
  GG           0           0                                          
  rs1805096    AA          73                    6.26 (3.74, 18.39)   0.272
  GA           17          12.52 (4.05, 19.80)                        
  GG           1           1.43                                       
  rs3790434    CC          61                    6.34 (3.57,19.08)    0.647
  CT           28          8.21 (4.12,18.96)                          
  TT           2           4.68 (4.40,4.95)                           
  rs3806318    AA          69                    6.48 (3.92,19.85)    0.396
  GA           19          10.81 (3.52,15.92)                         
  GG           3           3.69 (3.61,5.21)                           
  rs7518632    AA          65                    6.48 (3.66,19.08)    0.632
  CA           17          10.96 (4.18,19.80)                         
  CC           9           5.54 (2.95,14.27)                          

SNP: single‐nucleotide polymorphism; M: median.
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Haplotype analyses {#jcmm13093-sec-0010}
------------------

Five main haplotypes (AATC, GATC, GGCA, GGCC and GGTA) for *LEP* gene and five main haplotypes (ACACGACGC, ACGCAGCAA, ACGGAGCAA, ATGCAGCAA and GCGCAGCAA) for *LEPR* gene were identified using SHEsis software (Tables [7](#jcmm13093-tbl-0007){ref-type="table-wrap"} & [8](#jcmm13093-tbl-0008){ref-type="table-wrap"}). The results revealed that the haplotypes ACGCAGCAA and ATGCAGCAA were significantly associated with SLE, and the ACGCAGCAA appeared to be a significant protective haplotype (*P* = 0.003, OR = 0.745, 95% CI: 0.615--0.903; *P* = 0.038, OR = 1.390, 95% CI: 1.018--1.897).

###### 

Haplotype analysis of four SNPs in *LEP* gene in patients with SLE and controls

  Haplotype                                      Case \[*n* (%)\]   Control \[*n* (%)\]   χ^2^    *P* value   OR (95% CI)
  ---------------------------------------------- ------------------ --------------------- ------- ----------- ----------------------
  rs2167270‐ rs12706832‐ rs2071045‐ rs11761556                                                                
  AATC                                           223.98 (17.7)      178.29 (15.9)         1.308   0.253       0.881 (0.710, 1.094)
  GATC                                           51.11 (4.0)        55.50 (5.0)           1.193   0.275       1.242 (0.841, 1.833)
  GGCA                                           646.32 (51.1)      577.65 (51.7)         0.089   0.765       1.025 (0.870, 1.209)
  GGCC                                           64.28 (5.1)        57.97 (5.2)           0.014   0.906       1.022 (0.710, 1.472)
  GGTA                                           226.09 (17.9)      201.06 (18.0)         0.006   0.939       1.008 (0.817, 1.245)

Total χ^2^ = 2.274, *P* = 0.069.

All the haplotypes with a frequency \<0.03 were ignored in the analysis.
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###### 

Haplotype analysis of four SNPs in *LEPR* gene in patients with SLE and controls

  Haplotype                                                                                             Case \[*n* (%)\]   Control \[*n* (%)\]   χ^2^    *P* value   OR (95% CI)
  ----------------------------------------------------------------------------------------------------- ------------------ --------------------- ------- ----------- ----------------------
  rs3806318‐ rs3790434‐ rs1137100‐ rs13306519‐ rs10749754‐ rs1137101‐ rs8179183‐ rs1805096‐ rs7518632                                                                
  ACACGACGC                                                                                             65.57 (5.2)        44.72 (4.0)           1.914   0.167       1.318 (0.891, 1.949)
  ACGCAGCAA                                                                                             587.70 (46.4)      577.78 (51.7)         9.038   **0.003**   0.745 (0.615, 0.903)
  ACGGAGCAA                                                                                             158.79 (12.5)      121.20 (10.8)         1.754   0.185       1.189 (0.920, 1.537)
  ATGCAGCAA                                                                                             110.74 (8.7)       72.77 (6.5)           4.327   **0.038**   1.390 (1.018, 1.897)
  GCGCAGCAA                                                                                             49.31 (3.9)        42.96 (3.8)           0.005   0.942       1.016 (0.668, 1.545)

Total χ^2^ = 10.469, *P* = 0.033. Bold value means *P*\<0.05.

All the haplotype with a frequency \<0.03 were ignored in the analysis.
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Discussion {#jcmm13093-sec-0011}
==========

Systemic lupus erythematosus is a severe autoimmune disease with multiple serological alterations and affecting various organs. Although the aetiology is still unclear, it is generally acknowledged that this disease has complex genetic and environmental backgrounds. Recent studies have shown that leptin levels are elevated in patients with SLE and involved in the pathogenesis of this disease [19](#jcmm13093-bib-0019){ref-type="ref"}, [20](#jcmm13093-bib-0020){ref-type="ref"}, [21](#jcmm13093-bib-0021){ref-type="ref"}, [22](#jcmm13093-bib-0022){ref-type="ref"}. However, some other groups have demonstrated lower or unchanged circulating leptin levels in patients with SLE compared to healthy controls [23](#jcmm13093-bib-0023){ref-type="ref"}, [24](#jcmm13093-bib-0024){ref-type="ref"}. Our recent work, a meta‐analysis, also found no significant difference in plasma/serum leptin level between patients with SLE and normal controls [25](#jcmm13093-bib-0025){ref-type="ref"}. Similar studies have also been conducted among various autoimmune diseases such as rheumatoid arthritis (RA) and osteoarthritis (OA) [26](#jcmm13093-bib-0026){ref-type="ref"}, [27](#jcmm13093-bib-0027){ref-type="ref"}, [28](#jcmm13093-bib-0028){ref-type="ref"}. A recent study showed that serum leptin level and serum leptin/leptin receptor ratio imbalance were positively correlated with anticyclic citrullinated peptide antibodies in RA [29](#jcmm13093-bib-0029){ref-type="ref"} and might act as a predictor for disease activity [30](#jcmm13093-bib-0030){ref-type="ref"}. Therefore, *LEP* and *LEPR* gene polymorphisms might affect its expression and activity, and thereby involved in SLE pathogenesis.

In the current study, we investigated the association of *LEP* and *LEPR* single‐nucleotide polymorphisms with susceptibility to SLE in a Chinese population. However, we failed to detect any significant association between these SNPs and SLE risk. This result is inconsistent with a previous study by Afroze *et al*. They firstly reported an association between *LEPR Q223R* polymorphisms and risk of SLE in 100 Kashmiri individuals [10](#jcmm13093-bib-0010){ref-type="ref"}. They found that the carriers of variant genotype (A/G + G/G) or G allele were at increased risk of SLE and the different genotypes of *LEPR Q223R* might be involved in the development of different clinical manifestations associated with SLE. However, the sample size of this study is relatively small to get a powerful conclusion. Another study by Zhao *et al*. [11](#jcmm13093-bib-0011){ref-type="ref"} also analysed the association of leptin pathway‐related gene polymorphisms with SLE risk in four different ancestral groups. Then, they conducted a trans‐ancestry meta‐analysis across four ancestral groups to elevate the overall effect among these SNPs. Their results suggested that although several SNPs showed weak associations, these associations did not remain significant after correction for multiple testing. This result was similar with our findings. We also examined the potential associations of *LEP* and *LEPR* gene polymorphisms with specific clinical characteristics in patients with SLE. In *LEP*, none of the SNPs were associated with any clinical characteristics except the rs2071045 polymorphism. The TT genotype and T allele frequencies of the rs2071045 were significantly increased in patients with pericarditis, suggesting that the T allele of rs2071045 in SLE might elevate the risk of pericarditis. In *LEPR*, we found positive association between the GA/GG genotype and G allele frequencies of the rs3806318 polymorphism and the risk of photosensitivity in patients with SLE. Our results also demonstrated that rs1137100 might increase the risk of skin photosensitivity in SLE; however, the differences did not reach the statistical significance after correction for multiple testing.

Previous studies have also evaluated the role of *LEP* and *LEPR* genes in multiple autoimmune diseases; however, the results are controversial [31](#jcmm13093-bib-0031){ref-type="ref"}, [32](#jcmm13093-bib-0032){ref-type="ref"}, [33](#jcmm13093-bib-0033){ref-type="ref"}, [34](#jcmm13093-bib-0034){ref-type="ref"}. A recent study demonstrated that the genotype and allele frequencies of the *LEP* rs2167270 gene polymorphism had no association with the risk of RA [31](#jcmm13093-bib-0031){ref-type="ref"}. However, Farrokhi *et al*. revealed a significant role of *LEP G‐2548‐A* and *LEPR Q223R* polymorphisms in the risk of multiple sclerosis and its severity [32](#jcmm13093-bib-0032){ref-type="ref"}. Furthermore, two recent studies showed that genetic polymorphisms of the leptin gene might influence lung function via Notch and JAK/STAT3 signalling pathway [34](#jcmm13093-bib-0034){ref-type="ref"}, [35](#jcmm13093-bib-0035){ref-type="ref"}. Thus, *LEP* and *LEPR* gene polymorphisms might influence the production and activity of inflammatory cytokines and thereby play a role in the development of various autoimmune diseases.

However, one limitation of our study should be acknowledged. The sample size for analysing the serum leptin level in patients with SLE may not be sufficient to get a solid conclusion. Therefore, the findings should be interpreted with caution; further studies with larger sample size are needed to confirm these results.

In conclusion, *LEP* and *LEPR* gene polymorphisms are not associated with genetic susceptibility to SLE in the Chinese population. However, some SNPs are associated with specific clinical phenotype of SLE, such as skin rash, pericarditis and arthritis. Compared with previous similar studies, some of these contradictions may be due to studies with different ethnic background, sample size, pathogenesis and patients with different disease activity, duration and treatment. Therefore, further studies based on larger sample size in different populations are required to confirm this result, and the gene--gene or genes--environment interaction should be taken into consideration.
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